Serum N1-Methylnicotinamide is Associated With Coronary Artery Disease in Chinese Patients.
We previously reported that serum N1-methylnicotinamide (me-Nam), an indicator of nicotinamide N-methyltransferase activity, is associated with obesity and diabetes mellitus in Chinese patients. However, whether nicotinamide N-methyltransferase plays a role in human coronary artery disease (CAD) remains to be elucidated. We aim to investigate the associations of serum me-Nam with CAD in Chinese patients.



Serum me-NAM was measured by liquid chromatography-mass spectrometry in patients with (n=230) or without (n=103) CAD as defined by coronary angiography. The severity of CAD was expressed by number of diseased coronary arteries. Serum me-Nam was higher (7.65 ng/mL versus 4.95 ng/mL, P<0.001) in patients with CAD than in those without. Serum me-Nam was positively correlated with high-sensitivity C-reactive protein and negatively correlated with high-density lipoprotein before and after adjustment for potential confounding variables (P≤0.002). In multivariable logistic regression analyses, compared with those in the lowest tertile of serum me-NAM levels, patients in the top tertile had the highest risks for CAD (odds ratio, 4.21; 95% CI, 1.97-8.97 [P<0.001]). After adjustment for potential confounding variables, serum me-NAM was also increased from 0- to 3-vessel disease (P for trend=0.01).



Serum me-Nam is strongly associated with presence and severity of CAD, suggesting nicotinamide N-methyltransferase as a potential target for treating atherosclerosis in humans.
Department of Cardiology, Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.|Institute of Hypertension, Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Ming
M
Liu
Department of Clinical Pharmacology, Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Jihong
J
Chu
Department of Cardiology, Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Yang
Y
Gu
Department of Cardiology, Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Haibo
H
Shi
Department of Cardiology, Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Rusheng
R
Zhang
Department of Cardiology, Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Lingzhun
L
Wang
Department of Cardiology, Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Jiandong
J
Chen
Department of Cardiology, Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Le
L
Shen
Department of Cardiology, Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Peng
P
Yu
Department of Cardiology, Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Xiaohu
X
Chen
Department of Clinical Pharmacology, Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China zxwang518@sina.com wzhju333@163.com.
Wenzheng
W
Ju
Department of Cardiology, Jiangsu Province Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China zxwang518@sina.com wzhju333@163.com.
Zhenxing
Z
Wang
D000368:Aged; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D002681:China / Q000453:epidemiology; D002853:Chromatography, Liquid / Q000379:methods; D015897:Comorbidity; D017023:Coronary Angiography / Q000379:methods; D003324:Coronary Artery Disease / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology; D003920:Diabetes Mellitus / Q000097:blood / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008297:Male; D013058:Mass Spectrometry / Q000379:methods; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000097:blood; D050903:Nicotinamide N-Methyltransferase / Q000097:blood; D009765:Obesity / Q000097:blood / Q000453:epidemiology*; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012720:Severity of Illness Index
D015415:Biomarkers; D009536:Niacinamide; D050903:Nicotinamide N-Methyltransferase; C024058:N(1)-methylnicotinamide
N1‐methylnicotinamide; coronary angiography; coronary artery disease; inflammation